Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Accured Expenses: 2018-2024

Historic Change in Accured Expenses for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to $35.2 million.

  • Avidity Biosciences' Change in Accured Expenses rose 154.49% to $35.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 250.68%. This contributed to the annual value of $35.2 million for FY2024, which is 1018.70% up from last year.
  • Avidity Biosciences' Change in Accured Expenses amounted to $35.2 million in FY2024, which was up 1,018.70% from $3.1 million recorded in FY2023.
  • Avidity Biosciences' 5-year Change in Accured Expenses high stood at $35.2 million for FY2024, and its period low was $3.1 million during FY2023.
  • Over the past 3 years, Avidity Biosciences' median Change in Accured Expenses value was $18.3 million (recorded in 2022), while the average stood at $18.9 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first slumped by 82.83% in 2023, then skyrocketed by 1,018.70% in 2024.
  • Yearly analysis of 5 years shows Avidity Biosciences' Change in Accured Expenses stood at $5.7 million in 2020, then climbed by 5.11% to $6.0 million in 2021, then soared by 203.08% to $18.3 million in 2022, then plummeted by 82.83% to $3.1 million in 2023, then skyrocketed by 1,018.70% to $35.2 million in 2024.